The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy
Authors:
- Bernd GronerBGBernd Groner
- 1 August 2004
- journal article
- review article
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 14 (4) , 287-295
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signalingJournal of Cancer Research and Clinical Oncology, 2003
- Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor GrowthIn vivoHormone and Metabolic Research, 2003
- Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancerCancer Gene Therapy, 2002
- Expression of an IGF‐I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cellsInternational Journal of Cancer, 2002
- Cooperative Regulation of the Invasive and Metastatic Phenotypes by Different Domains of the Type I Insulin-like Growth Factor Receptor β SubunitJournal of Biological Chemistry, 2001
- Genetic Selection of Peptide Inhibitors of Biological PathwaysScience, 1999
- The Insulin-Like Growth Factor-I Receptor Signaling Pathways Are Important for Tumorigenesis and Inhibition of ApoptosisCritical Reviews™ in Oncogenesis, 1997
- Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2Nature, 1996
- Mutant IGF-I Receptors as Dominant Negatives for Growth and TransformationBiochemical and Biophysical Research Communications, 1995
- An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue cultureBiochemical and Biophysical Research Communications, 1987